Parexel CEO sells $2.4M in stock
![Parexel CEO sells $2.4M in stock](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_small/9/9/1/8/508199-1-eng-GB/Parexel-CEO-sells-2.4M-in-stock.jpg)
The stock was worth $2.485M, according to SEC documents. Von Rickenbach still owns about $30M in stock, according to news reports.
The sell-off comes as Parexel recently exceeded expectations with its second quarter results.
Analysts at Barclays raised their price target on Parexel shares from $48.00 to $52.00 in a research note from last week, while analysts at ISI Group upgraded shares of the company’s stock from a “buy” rating to a “strong-buy” rating in a research note to investors on Wednesday, January 22nd.
And analysts at Thomson Reuters/Verus downgraded shares of Parexel. One research analyst has rated the stock with a sell rating, seven have given it a hold rating, five have offered a buy rating and two have said the stock deserves a strong buy rating, according to reports.